- Home
- CAES vs IPSC Comparison
CAES vs IPSC Comparison
Compare CAES & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAES | IPSC |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.5M | 362.5M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAES | IPSC |
|---|---|---|
| Price | $10.09 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 22.2K | ★ 452.3K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $10.05 | $0.44 |
| 52 Week High | $10.12 | $2.97 |
Technical Indicators
Market Signals| Indicator | CAES | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 51.77 |
| Support Level | $10.06 | $1.88 |
| Resistance Level | $10.11 | $2.39 |
| Average True Range (ATR) | 0.01 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.00 | 61.11 |
Price Performance
Historical ComparisonAbout CAES Cantor Equity Partners VII Inc. Class A Ordinary Shares
Cantor Equity Partners VII Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.